225Ac-3BP-3940 / 3B Pharma, Curanosticum - LARVOL DELTA

FAP-directed Radiopharmaceutical Therapy in metastatic gastrointestinal carcinoma as rescue therapy after failure of conventional treatments: A retrospective analysis on safety, efficacy and survival (EANM 2025) - "Previous treatments: chemotherapy (96%); surgery of primary (61%); external beam radiation therapt of primary or metastases (61%); therapy with Bevacizumab (56%); surgery of metastases (35%); ICPi (39%); TKi (39%). 65 FRT cycles were totally administered over 48 months (monotherapies: thirty-six 177Lu-3BP-3940, eight 90Y-3BP-3940, three 225Ac-3BP-3940; TANDEM: fifteen 225Ac/177Lu-3BP-3940, three 225Ac/90Y-3BP-3940)...At analysis, 8 patients were alive (follow-up: 2-27 months) and 15 had died (survival: 3 days-15 months). Conclusion FRT with radiolabelled-3BP-3940 is overall safe for patients with advanced GI carcinoma. Considering its palliative purpose , both therapy response and survival were encouraging , but larger, prospective trials are needed to improve clinical outcome."

Metastases • Retrospective data • Anal Carcinoma • Anemia • Biliary Cancer • Cholangiocarcinoma • Chronic Kidney Disease • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Leukopenia • Nephrology • Oncology • Renal Disease • Solid Tumor • Thrombocytopenia • FAP

Radiopharmaceutical Therapy in Neuroendocrine Carcinoma using Actinium-225, FAP-targeting, and somatostatin receptor antagonists: A new therapeutic perspective in patients progressing to standard therapies (EANM 2025) - "Previous treatments: CHT (n=5); EBRT (n=4); surgery (n=3); SST analogues (n=2); Everolimus (n=1); 177Lu-DOTATATE (n=1)...Four patients received FRT as follows: one cycle of 90Y-3BP-3940; one cycle of 225Ac/177Lu-3BP-3940 (TANDEM); two cycles of 177Lu-3BP-3940 and one of 90Y-3BP-3940; one cycle of 225Ac-3BP-3940 and three of 225Ac/177Lu-3BP-3940 (TANDEM)...At analysis, 5 patients had died, 1 patient was alive. Conclusion Our experience shows that RPT can offer a therapeutic chance in patients with advanced NEC exhausting other treatments , however response rates were low; further research is needed to enhance RPT efficacy, also exploring the synergistic effects of combination with other therapeutic strategies."

Clinical • Anemia • Endocrine Cancer • Hematological Disorders • Hepatocellular Cancer • Leukopenia • Neuroendocrine Carcinoma • Oncology • Pancreatic Cancer • Solid Tumor • Thrombocytopenia • SSTR

Novel FAP-Targeted Radiopharmaceutical Therapy with 177 Lu/ 90 Y/ 225 Ac-3BP-3940 in Patients with Pancreatic Ductal Adenocarcinoma (PDAC) (EANM 2025) - No abstract available

Clinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Targeting metastatic breast cancer with Actinium-225 FAP-directed radiopharmaceutical therapy: a retrospective analysis of safety, efficacy and survival (SNMMI 2025) - "Hydration was provided during and after each cycle; premedication (antiemetics and/or dexamethasone) was given in selected cases...Previous treatments included chemotherapy 100%; surgery of the primary tumor 89%; hormonal therapy 78%; loco-regional radiotherapy 56%; therapy with Denosumab, Bevacizumab and PARP inhibitors (33%, respectively); immune-checkpoint inhibitors 22%; Trastuzumab 22%; β-FRT 22%... Despite the limited sample size and retrospective nature of this study, α-FRT with 225Ac-3BP-3940 appears to be a well-tolerated and effective treatment for metastatic BCa with otherwise limited therapeutic options. Its favorable safety profile and encouraging survival outcomes (up to nearly two years) support its potential role in advanced BCa, warranting further investigation through larger, prospective clinical trials."

Metastases • Retrospective data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Palliative care • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • FAP • HER-2

FAP-Targeted Radiopharmaceutical Therapy using 177Lu-, 90Y- and 225Ac-labeled 3BP-3940 in a Cohort of 88 Patients with 21 Different Advanced Malignancies (SNMMI 2025) - "Administrations of 177Lu-/90Y-/225Ac-3BP-3940 (with cumulative administered radioactivity per patient and range of 177Lu, 17.4 ± 13.0 GBq; 90Y, 6.9 ± 3.9 GBq; and 225Ac 13.4 ± 10.0 MBq) were in general well tolerated. Pain was observed in 11/88 patients (16%) including pain flare in 9/88 (13%), nausea in 11/88 (13%), vomiting in 6/88 (7%), headache in 2/88 (2%), diarrhea 3/88 (3%), a temporary rise in body temperature for one day in 4/88 (2%), partial alopecia (hair loss) in 7/88 (8%), and intensified fatigue in 4/88 patients (7%); no other clinically relevant adverse symptoms or clinically detectable pharmacologic effects were noticed or reported in any of the patients. Dosimetry was calculated for one pancreatic cancer patient who received 9.73 GBq 177Lu-3BP-3940: absorbed radiation doses were as follows: brain 37 mGy, lungs 168 mGy, healthy liver tissue 86 mGy, pancreas 142 mGy, kidneys 265 mGy, and 2200 mGy for the primary pancreatic adenocarcinoma."

Clinical • Metastases • Alopecia • Fatigue • Immunology • Oncology • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor

FAP-directed radiopharmaceutical therapy of metastatic pancreas adenocarcinoma with alpha-emitting Actinium-225 or in TANDEM (remote) (SNMMI 2025) - "Therapy was performed with palliative purpose and all patients signed informed consent; premedication with antiemetics and/or dexamethasone was administered in selected cases. Our retrospective analysis shows that α-FRT with 225Ac-3BP-3940 (both as monotherapy and in TANDEM with β-emitters) in metastatic PDAC patients who have exhausted conventional therapies is a valuable treatment possibility, showing good safety with acceptable acute adverse events (transient) and long-term toxicity (mainly of mild grade; the only two cases of liver impairment at G3 level occurred in patients with hepatic metastases and pre-FRT hepatic function alterations). α-FRT achieved promising outcomes, with 27% partial remissions and survival extending beyond one year from the first 225Ac-3BP-3940 administration, highlighting its potential in aggressive, treatment-resistant and rapidly progressive PDAC."

Metastases • Anemia • Hematological Disorders • Hepatocellular Cancer • Hepatology • Leukopenia • Liver Failure • Oncology • Pain • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thrombocytopenia • FAP

A retrospective analysis of safety, efficacy and survival of metastatic colorectal cancer patients treated with Actinium-225 FAP-directed radiopharmaceutical therapy (remote) (SNMMI 2025) - "Premedication (antiemetics/dexamethasone) was administered as needed... We studied 7 males and 3 females (age range 40-75 years at the time of the first α-FRT), previously treated with chemotherapy 100%; surgery of the primary 80%; surgery of metastases 60% (mainly in the liver, 40%); immunotherapy with Bevacizumab 90%; radiotherapy of the primary or metastases 60%; immune-checkpoint inhibitors 30%; β-FRT 50%... Our retrospective analysis shows that α-FRT as monotherapy with 225Ac-3BP-3940 or in TANDEM with β-emitters is a safe treatment option for patients with metastatic progressive CRC, without significant acute adverse events or long-term nephrotoxicity and with manageable long-term hematological toxicity; hepatotoxicity G2/G3 was documented in two patients with hepatic metastases. Considering the palliative purpose of 225Ac-3BP-3940 FRT in a metastatic advanced setting, both therapy response and survival outcomes were overall encouraging. Larger, prospective..."

Metastases • Retrospective data • Anemia • Colorectal Cancer • Fatigue • Hematological Disorders • Hepatocellular Cancer • Leukopenia • Oncology • Pain • Solid Tumor • FAP